Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Inc.

www.seattlegenetics.com

Latest From Seattle Genetics Inc.

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies

Keeping Track: Recarbrio Approval Highlights Two-Week Roundup

The latest drug development news and highlights for our US FDA Performance Tracker.

Approvals Drug Review

ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going

The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.

Financing Cancer

So Far, Still So Good For Seattle Genetics/Astellas’ Bladder Cancer ADC

Updated data from the Phase II EV-201 study of Seattle Genetics/Astellas Pharma’s novel ADC are strong enough to warrant accelerated approval, its investigators claim. An accelerated submission to the US FDA is due later this year.

ASCO Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register